The Dermatologist’s Approach to Onychomycosis
Abstract
:1. Introduction
Mimickers of Onychomycosis | Reference |
---|---|
Psoriasis | [1] |
Lichen Planus | |
Bacterial Infections | |
Onychogryphosis | |
Traumatic onychodystrophies | |
Yellow Nail Syndrome | |
Toenail Cellulitis | |
Contact Dermatitis | |
Nail-bed Tumors | |
Onycholysis, nonspecific | |
Pachyonychia Congenita |
2. Terminology
Subtypes of Onychomycosis | Reference |
---|---|
Distal lateral subungual onychomycosis (DLSO) | [1] |
White superficial onychomycosis (WSO) | |
Proximal subungual onychomycosis (PSO) | |
Endonyx onychomycosis (EO) | |
Candidal onychomycosis |
3. Prevalence and Risk Factors
4. Diagnosis
5. Determining Severity and Outcomes
6. To Treat or Not to Treat?
7. Systemic Therapies
8. New Topical Therapies
9. Laser and Light Devices
9.1. Nd:YAG
9.2. Carbon Dioxide Laser
9.3. UV Light Therapy
9.4. Photodynamic Therapy
9.5. Dual Wavelength 870-/930-nm Laser
10. Managing Expectations for Increased Patient Satisfaction
11. Conclusions
Conflicts of Interest
References
- Scher, R.K.; Daniel, C.R., III. Nails: Therapy, Diagnosis, Surgery, 3rd ed.; Elsevier Saunders: Philadelphia, PA, USA, 2005; pp. 127–170. [Google Scholar]
- Crissey, J.T. Common dermatophyte infections. A simple diagnostic test and current management. Postgrad. Med. 1998, 103, 191–192, 197–200, 205. [Google Scholar] [CrossRef] [PubMed]
- Kemna, M.E.; Elewski, B.E. A U.S. epidemiologic survey of superficial fungal diseases. J. Am. Acad. Dermatol. 1996, 35, 539–542. [Google Scholar] [CrossRef]
- Elewski, B.E. Onychomycosis. Treatment, quality of life, and economic issues. Am. J. Clin. Dermatol. 2000, 1, 19–26. [Google Scholar] [CrossRef] [PubMed]
- Elewski, B.E. Onychomycosis: Pathogenesis, diagnosis, and management. Clin. Microbiol. Rev. 1998, 11, 415–429. [Google Scholar] [CrossRef] [PubMed]
- Zaias, N.; Glick, B.; Rebell, G. Diagnosing and treating onychomycosis. J. Fam. Pract. 1996, 42, 513–518. [Google Scholar] [PubMed]
- Elewski, B.E.; Rich, P.; Tosti, A.; Pariser, D.M.; Scher, R.; Daniel, R.C.; Gupta, A.K. Onychomycosis: An Overview. J Drugs Dermatol. 2013, 12, s96–s103. [Google Scholar] [CrossRef] [PubMed]
- Cohen, J.L.; Scher, R.K.; Pappert, A.S. The nail and fungus infections. In Cutaneous Fungal Infections; Elewski, B., Ed.; Igaku-Shoin Inc.: New York, NY, USA, 1992; pp. 106–122. [Google Scholar]
- Heikkilä, H.; Stubb, S. The prevalence of onychomycosis in Finland. Br. J. Dermatol. 1995, 133, 699–703. [Google Scholar] [CrossRef] [PubMed]
- Elewski, B.E.; Charif, M.A. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch. Dermatol. 1997, 133, 1172–1173. [Google Scholar] [CrossRef] [PubMed]
- Gupta, A.K.; Sibbald, R.G.; Lynde, C.W.; Hull, P.R.; Prussick, R.; Shear, N.H.; de Doncker, P.; Daniel, C.R., III; Elewski, B.E. Onychomycosis in children: Prevalence and treatment strategies. J. Am. Acad. Dermatol. 1997, 36, 395–402. [Google Scholar] [CrossRef]
- Kaçar, N.; Ergin, S.; Ergin, C.; Erdogan, B.S.; Kaleli, I. The prevalence, aetiological agents and therapy of onychomycosis in patients with psoriasis: A prospective controlled trial. Clin. Exp. Dermatol. 2007, 32, 1–5. [Google Scholar] [PubMed]
- Gupta, A.K.; Lynde, C.W.; Jain, H.C.; Sibbald, R.G.; Elewski, B.E.; Daniel, C.R., III; Watteel, G.N.; Summerbell, R.C. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: A multicentre study. Br J Dermatol. 1997, 136, 786–789. [Google Scholar] [CrossRef] [PubMed]
- Carney, C.; Tosti, A.; Daniel, R.; Scher, R.; Rich, P.; de Coster, J.; Elewski, B. A new classification system for grading the severity of onychomycosis; Onychomycosis Severity Index. Arch. Dermatol. 2011, 147, 1277–1282. [Google Scholar] [CrossRef] [PubMed]
- Rich, P. Topical treatment of onychomycosis with efinaconazole solution 10%. Cutis 2013, 91, 305–307. [Google Scholar] [PubMed]
- Drake, L.A.; Patrick, D.L.; Fleckman, P.; Andr, J.; Baran, R.; Haneke, E.; Sapède, C.; Tosti, A. The impact of onychomycosis on quality of life: Development of an international onychomycosis-specific questionnaire to measure patient quality of life. J. Am. Acad. Dermatol. 1999, 41, 189–196. [Google Scholar] [CrossRef]
- Scher, R.K. Onychomycosis: A significant medical disorder. J. Am. Acad. Dermatol. 1996, 35, S2–S5. [Google Scholar] [CrossRef]
- De Backer, M.; de Vroey, C.; Lesaffre, E.; Scheys, I.; de Keyser, P. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: A double-blind comparative trial of terbinafine 250 mg/day vs. itraconazole 200 mg/day. J Am Acad Dermatol. 1998, 38, S57–S63. [Google Scholar] [CrossRef]
- Scher, R.K.; Breneman, D.; Rich, P.; Savin, R.C.; Feingold, D.S.; Konnikov, N.; Shupack, J.L.; Pinnell, S.; Levine, N.; Lowe, N.J.; et al. Once-weekly fluconazole (150, 300 or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. J. Am. Acad. Dermatol. 1998, 38, S77–S86. [Google Scholar] [CrossRef]
- Baudraz-Rosselet, F.; Ruffleux, C.; Lurati, M.; Bontems, O.; Monod, M. Onychomycosis insensitive to systemic terbinafine and azole treatments reveals non-dermatophyte moulds as infectious agents. Dermatology 2010, 220, 164–168. [Google Scholar] [CrossRef] [PubMed]
- Gupta, A.K.; Joseph, W.S. Ciclopirox 8% nail lacquer in the treatment of onychomycosis of the toenails in the United States. J. Am. Podiatr. Med. Assoc. 2000, 90, 495–501. [Google Scholar] [CrossRef] [PubMed]
- Gupta, A.K.; Fleckman, P.; Baran, R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J. Am. Acad. Dermatol. 2000, 43, S70–S80. [Google Scholar] [CrossRef] [PubMed]
- Rogers, P.; Bassler, M. Treating onychomycosis. Am. Fam. Phys. 2001, 63, 663–673. [Google Scholar]
- Brenner, M.A.; Harkless, L.B.; Mendicino, R.W.; Page, J.C. Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: A multicenter, open-label study. J. Am. Podiatr. Med. Assoc. 2007, 97, 195–202. [Google Scholar] [CrossRef] [PubMed]
- Gupta, A.K.; Simpson, F.C. Routes of drug delivery into the nail apparatus: Implications for the efficacy of topical nail solutions in onychomycosis. J. Dermatol. Treat. 2015, 18, 1–3. [Google Scholar] [CrossRef] [PubMed]
- Bhatt, V.; Pillai, R. Efinaconazole Topical Solution, 10%: Formulation Development Program of a New Topical Treatment of Toenail Onychomycosis. J. Pharm. Sci. 2015, 10, 10–12. [Google Scholar] [CrossRef] [PubMed]
- Jo Siu, W.J.; Tatsumi, Y.; Senda, H.; Pillai, R.; Nakamura, T.; Sone, D.; Fothergill, A. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis. Antimicrob. Agents Chemother. 2013, 57, 1610–1616. [Google Scholar] [CrossRef] [PubMed]
- Tatsumi, Y.; Nagashima, M.; Shibanushi, T.; Iwata, A.; Kangawa, Y.; Inui, F.; Siu, W.J.; Pillai, R.; Nishiyama, Y. Mechanism of antifungal action of efinaconazole, a novel triazole agent. Antimicrob. Agents Chemother. 2013, 57, 2405–2409. [Google Scholar] [CrossRef] [PubMed]
- Rodriguez, D.A. Efinaconazole Topical Solution, 10%, for the treatment of Mild and Moderate Toenail Onychomycosis. J. Clin. Aesthet. Dermatol. 2015, 8, 24–29. [Google Scholar] [PubMed]
- Elewski, B.E.; Pollak, R.A.; Pillai, R.; Olin, J.T. Access of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual space. J. Drugs Dermatol. 2014, 13, 1394–1398. [Google Scholar] [PubMed]
- Zeichner, J.A.; Stein Gold, L.; Korotzer, A. Penetration of (14C)-Efinaconazole Topical Solution, 10%, Does Not Appear to be Influenced by Nail Polish. J. Clin. Aesthet. Dermatol. 2014, 7, 34–36. [Google Scholar] [PubMed]
- Elewski, B.E.; Rich, P.; Pollak, R.; Pariser, D.M.; Watanabe, S.; Senda, H.; Ieda, C.; Smith, K.; Pillai, R.; Ramakrishna, T.; Olin, J.T. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized double blind studies. J. Am. Acad. Dermatol. 2013, 68, 600–608. [Google Scholar] [CrossRef] [PubMed]
- Alley, M.R.K.; Baker, S.J.; Beutner, K.R.; Plattner, J. Recent progress in the topical therapy of onychomycosis. Expert Opin. Investig. Drugs 2007, 16, 157–167. [Google Scholar] [CrossRef] [PubMed]
- Kerydin (Package Insert); Anacor Pharmaceuticals, Inc.: Palo Alto, CA, USA, 2014.
- Rock, F.L.; Mao, W.; Yaremchuk, A.; Tukalo, M.; Crépin, T.; Zhou, H.; Zhang, Y.K.; Hernandez, V.; Akama, T.; Baker, S.J.; et al. An antifungal agent inhibits an aminoacyl-tRNA synthetase by trapping tRNA in the editing site. Science 2007, 316, 1759–1761. [Google Scholar] [CrossRef] [PubMed]
- Elewski, B.E.; Aly, R.; Baldwin, S.L.; González Soto, R.F.; Rich, P.; Weisfeld, M.; Wiltz, H.; Zane, L.T.; Pollak, R. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies. J. Am. Acad. Dermatol. 2015, 73, 62–69. [Google Scholar] [CrossRef] [PubMed]
- Hui, X.; Baker, S.J.; Wester, R.C.; Barbadillo, S.; Cashmore, A.K.; Sanders, V.; Hold, K.M.; Akama, T.; Zhang, Y.K.; Plattner, J.J.; et al. In Vitro Penetration of a Novel Oxaborole Antifungal (AN2690) into the Human Nail Plate. J. Pharm. Sci. 2007, 96, 2622–2631. [Google Scholar] [CrossRef] [PubMed]
- Yang, M.U.; Yaroslavsky, A.N.; Farinelli, W.A.; Flotte, T.J.; Rius-Diaz, F.; Tsao, S.S.; Anderson, R.R. Long-pulsed neodymium: Yttrium-aluminum-garnet laser treatment for port-wine stains. J. Am. Acad. Dermatol. 2005, 52, 480–490. [Google Scholar] [CrossRef] [PubMed]
- Hochman, L.G. Laser treatment of onychomycosis using a novel 0.65-millisecond pulsed Nd: YAG 1064-nm laser. J. Cosmet. Laser Ther. 2011, 13, 2–5. [Google Scholar] [CrossRef] [PubMed]
- Moon, S.H.; Hur, H.; Oh, Y.J.; Choi, K.H.; Kim, J.E.; Ko, J.Y.; Ro, Y.S. Treatment of onychomycosis with a 1064-nm long-pulsed Nd: YAG laser. J. Cosmet. Laser Ther. 2014, 16, 165–170. [Google Scholar] [CrossRef] [PubMed]
- Kimura, U.; Takeuchi, K.; Kinoshita, A.; Takamori, K.; Hiruma, M.; Suga, Y. Treating onychomycoses of the toenail: Clinical efficacy of the sub-millisecond 1064 nm Nd: YAG laser using a 5 mm spot diameter. J. Drugs Dermatol. 2012, 11, 496–504. [Google Scholar] [PubMed]
- Apfelberg, D.B.; Rothermel, E.; Widtfeldt, A.; Maser, M.R.; Lash, H. Preliminary report on use of carbon dioxide laser in podiatry. J. Am. Podiatry Assoc. 1984, 74, 509–513. [Google Scholar] [CrossRef] [PubMed]
- Borovoy, M.; Tracy, M. Noninvasive CO laser fenestration improves treatment of onychomycosis. Clin. Laser Mon. 1992, 10, 123–124. [Google Scholar] [PubMed]
- Cutler, T.D.; Zimmerman, J.J. Ultraviolet irradiation and the mechanisms underlying its inactivation of infections agents. Anim. Health Res. Rev. 2011, 12, 15–23. [Google Scholar] [CrossRef] [PubMed]
- Dai, T.; Tegos, G.P.; Rolz-Cruz, G.; Cumbie, W.E.; Hamblin, M.R. Ultraviolet C inactivation of dermatophytes: Implications for treatment of onychomycosis. Br. J. Dermatol. 2008, 158, 1239–1246. [Google Scholar] [CrossRef] [PubMed]
- Chronin, L.J.; Mildren, R.P.; Moffitt, M.; Lauto, A.; Morton, C.O.; Stack, C.M. An investigation into the inhibitory effect of UV radiation on T. rubrum. Lasers Med. Sci. 2014, 29, 157–163. [Google Scholar] [CrossRef] [PubMed]
- Sotiriou, E.; Koussidou-Eremonti, T.; Chaidemenos, G.; Apalla, Z.; Ioannides, D. Photodynamic therapy for distal and lateral subungual toenail onychomycosis caused by Trichophyton rubrum: Preliminary results of a single-centre open trial. Acta Derm. Venereol. 2010, 90, 216–217. [Google Scholar] [CrossRef] [PubMed]
- Piraccini, B.M.; Rech, G.; Tosti, A. Photodynamic therapy of onychomycosis caused by Trichophyton rubrum. J. Am. Acad. Dermatol. 2008, 59, S75–S76. [Google Scholar] [CrossRef] [PubMed]
- Bornstein, E.; Hermans, W.; Gridley, S.; Manni, J. Near-infrared photoinactivation of bacteria and fungi at physiologic temperatures. Photochem. Photobiol. 2009, 85, 1364–1374. [Google Scholar] [CrossRef] [PubMed]
- Landsman, A.S.; Robbins, A.H.; Angelini, P.F.; Wu, C.C.; Cook, J.; Oster, M.; Bornstein, E.S. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure. J. Am. Podiatr. Med. Assoc. 2010, 100, 166–177. [Google Scholar] [CrossRef] [PubMed]
- Landsman, A.S.; Robbins, A.H. Treatment of mild, moderate, and severe onychomycosis using 870- and 930-nm light exposure: Some follow-up observations at 270 days. J. Am. Podiatr. Med. Assoc. 2012, 102, 169–171. [Google Scholar] [CrossRef] [PubMed]
- Bhatia, N. Managing Assessments and Expectations: Patient Responses Following Therapy with Efinaconazole Topical Solution, 10%. J. Drugs Dermatol. 2015, 14, 694–698. [Google Scholar] [PubMed]
- Rich, P. Efinaconazole topical solution, 10%: The benefit of treating onychomycosis early. J. Drugs Dermatol. 2015, 14, 58–62. [Google Scholar] [PubMed]
© 2015 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license ( http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Queller, J.N.; Bhatia, N. The Dermatologist’s Approach to Onychomycosis. J. Fungi 2015, 1, 173-184. https://doi.org/10.3390/jof1020173
Queller JN, Bhatia N. The Dermatologist’s Approach to Onychomycosis. Journal of Fungi. 2015; 1(2):173-184. https://doi.org/10.3390/jof1020173
Chicago/Turabian StyleQueller, Jenna N., and Neal Bhatia. 2015. "The Dermatologist’s Approach to Onychomycosis" Journal of Fungi 1, no. 2: 173-184. https://doi.org/10.3390/jof1020173
APA StyleQueller, J. N., & Bhatia, N. (2015). The Dermatologist’s Approach to Onychomycosis. Journal of Fungi, 1(2), 173-184. https://doi.org/10.3390/jof1020173